Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00942734
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    One tablet (150 mg) by mouth every day of each 28 day study cycle.
  • RAD001 — DRUG
    1 tablet (5 mg) by mouth every day of each 28 day study cycle.

Study Details

The goal of this clinical research study is to learn if RAD001 in combination with Tarceva (erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC). The safety of this drug combination will also be studied.

Key Dates

First listed
Jul 21, 2009
Start date
Jul 31, 2009
Status verified
Jun 2026
Primary completion
Nov 30, 2014
Completion
Nov 30, 2014

Study Design

Enrollment
49 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: RAD001 + Erlotinib
    RAD001 1 tablet (5 mg) by mouth every day of each 28 day study cycle. Erlotinib one tablet (150 mg) by mouth every day of each 28 day study cycle.

Primary Outcome Measure

12-Week Progression-Free Survival (PFS) [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Head and neck cancer
By specialty
OncologyENT
By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies